7/102 sources · 2 publishersUpdated Nov 18, 18:37 UTC
Bernstein downgrades Summit Therapeutics to Underperform over FDA rejection of lead asset
Bernstein Research lowered its rating on Summit Therapeutics to Underperform, citing concerns about the company's research and development capabilities after the U.S. Food and Drug Administration declined to approve its lead drug, ivonescimab, which was co‑developed with Akeso. The downgrade was issued on 18 November 2026.
Why it matters
The downgrade may pressure Summit Therapeutics' share price and could affect investors' valuation of the company, as analysts' ratings often influence market sentiment.
Key facts
- 1Bernstein downgraded Summit Therapeutics to Underperform. seekingalpha.com
- 2The downgrade was based on the FDA's rejection of ivonescimab, Summit's lead asset developed with Akeso. tokenpost.com
- 3The downgrade was announced on 18 November 2026. seekingalpha.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.